Vicore Pharma Holding AB

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company based in Sweden, specializing in the development of innovative therapies targeting severe respiratory and fibrotic diseases, particularly through angiotensin II type 2 receptor agonists (ATRAGs). Its lead candidate, Buloxibutid (C21), is a first-in-class oral small molecule ATRAG in Phase 2b clinical trials for idiopathic pulmonary fibrosis (IPF), with Orphan Drug and Fast Track designations from the FDA, and under investigation for pulmonary arterial hypertension. The company also advances Almee, an investigational digital therapeutic medical device based on cognitive behavioral therapy, which has completed Phase III trials and received FDA Breakthrough Device Designation to mitigate the psychological effects of pulmonary fibrosis. Vicore collaborates with partners like Emeriti Bio AB, HaLaCore Pharma AB, and Alex Therapeutics AB to expand its pipeline, including follow-on ATRAG molecules and digital apps for interstitial lung diseases. Founded in 2000 and headquartered in Stockholm with 29 employees, Vicore Pharma Holding AB plays a key role in the biotechnology sector, focusing on disease-modifying treatments in healthcare.